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Dissertation abstract 
The diagnostic accuracy of serum prolidase activity as a 
marker for liver fibrosis in suspected liver disease 
 
Hypothesis 
Serum prolidase activity correlates with the degree of hepatic fibrosis and can be used 
to assess the presence and the degree of fibrosis. 
 
Abstract 
Liver dysfunction is common, often unrecognised and likely to increase in incidence in 
the population in parallel with the obesity and attendant type 2 diabetes mellitus 
epidemics.  Liver fibrosis is a significant finding in liver pathology as it imparts important 
clinical staging and prognostic information, is a risk marker of adverse clinical outcome 
and yet, even if advanced, is capable of reversal with appropriate therapy.   Histological 
examination of liver biopsy material is the reference standard in the assessment of liver 
fibrosis, but it is impractical to biopsy all patients who are suspected of having liver 
disease and furthermore there are associated drawbacks.  No current biomarker or 
imaging technique performs satisfactorily in diagnosing and/or staging liver fibrosis.  
Several novel biomarkers have been described for this purpose.  This dissertation 
evaluated the measurement and the diagnostic accuracy of one such biomarker, serum 
prolidase, in determining the potential presence and degree of liver fibrosis compared 
with liver biopsy. 
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Part A describes the scope of the problem, the rationale for the study and the potential 
impact of the findings.  Part B, a literature review, examines the use and limitations of 
liver biopsy, clinical imaging techniques and other biochemical markers.  It provides 
background on prolidase and discusses important published research findings.  Part C 
details a prospective case control study undertaken by the author, supervisors and 
collaborators to evaluate the methods used in the measurement of prolidase activity 
and to determine its diagnostic accuracy compared with liver biopsy.  Part D contains 
supplementary information and appendices such as details of the methodology used, 
ethics approval letters, the informed consent and the university guidelines inter alia.. 
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Part A Protocol 
Part A of this mini-dissertation is written as per the official University of Cape Town 
guidelines (see Appendix).  This section is a protocol which provides background and 
motivation for the research, the structure of the proposed research and its likely impact. 
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Part A 
Evaluation of serum prolidase activity as a marker for liver 
fibrosis in suspected liver disease. 
 
Project author 
  Dr JC Stanfliet, Division of Chemical Pathology, UCT & NHLS 
Supervisors 
 Primary:  
Prof TS Pillay, previously Head of the Division of Chemical Pathology, UCT 
& NHLS; currently Deputy Vice Chancellor, University of Kwazulu-Natal 
 Secondary:  
Dr Peter Berman, Division of Chemical Pathology, UCT & NHLS 
 
Collaborator 
  Dr Michael Locketz, Division of Anatomical pathology, UCT & NHLS 
 
Summary 
Liver injury is very common yet often clinically silent.  The identification of such injury 
will allow for appropriate medical management.  The current reference standard for the 
determination of liver fibrosis is histological examination of liver biopsy material.  No 
current clinical imaging technique or biochemical marker can match the sensitivity and 
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specificity of biopsy.  Serum prolidase is a novel biomarker that has shown promise in 
several studies in the diagnosis of liver fibrosis.   
 
Aims and objectives  
The specific objectives of this project are to: 
a) Establish the methodology for the serum prolidase assay in our laboratory; 
b) Evaluate the prolidase assay method; 
c) Establish whether there is a significant difference in serum prolidase activity 
when histological fibrosis is present; 
d) Establish whether hepatic fibrosis can be identified early in susceptible patients 
by means of serum prolidase; 
e) Establish whether serum prolidase activity correlates with the degree of hepatic 
fibrosis; 
f) Establish a baseline for the future determination of a reference interval for 
serum prolidase activity in the local population. 
 
Hypothesis 
Serum prolidase activity correlates with the degree of hepatic fibrosis and can be used 
as an indicator of the degree of fibrosis. 
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Background 
The liver is essential for many homeostatic functions, including the maintenance of 
blood glucose levels, the manufacture of all circulating proteins in blood apart from 
immunoglobulins, biotransformation of endogenous and exogenous waste products, 
and the metabolism of many hormones.  It is also central to cholesterol and bile acid 
metabolism.
1
   
 
Damage to the liver results in orchestrated healing, but if the damage is chronic, fibrosis 
may develop.
2,3
  If this continues there is eventual alteration of liver architecture, with 
islands of hepatocyte regeneration in a background of excessive fibrosis, a condition 
termed cirrhosis.
1,3-6
  Chronic liver injury comprises a spectrum of steatosis, hepatitis, 
fibrosis, cirrhosis and hepatocellular carcinoma (HCC).  Patients often present late, as 
the liver has a significant reserve capacity and can regain normal function even in the 
setting of advanced fibrosis.
1,7
 
 
The assessment of hepatic fibrosis is a clinical requirement to establish the presence and 
staging of fibrosis and cirrhosis, to determine the prognosis, available treatment 
options, and to detect any ensuing complications.
8-10
  Reversal of injury and recovery of 
function is possible even in the setting of advanced disease with appropriate 
therapy.
3,5,11
  In addition, monitoring the response to treatment is required if anti-viral 
and anti-fibrotic therapies are instituted.
12
   In reality, there is no current licensed 
specific treatment for liver fibrosis, and management consists of stopping the 
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aetiological agent and avoiding further insults to the liver.
1
  By inference, the earlier the 
pathology is detected, the better the outcome will be, given the propensity for the liver 
to recover.   
 
Several authors estimate the incidence of liver dysfunction at a third of the adult 
population in the United States of America.
13-15
  Globally, the major aetiological factors 
causing liver injury are viral infections, alcohol and non-alcoholic fatty liver disease 
(NAFLD).
1,6,16
  The World Health Organisation (WHO) estimates that 350 million people 
are infected with chronic hepatitis B and 180 million with chronic hepatitis C and half of 
patients chronically infected with hepatitis C eventually develop fibrosis and 20% 
cirrhosis.
9
  A similar proportion of people with alcoholic or non-alcoholic steatohepatitis 
(NASH) will develop cirrhosis.
16,17
  A recent screening program in France estimated the 
population prevalence of liver fibrosis at 2.8%.
11
  The incidence of hepatic fibrosis is 
likely to increase because of the rapid increase in obesity as well as type 2 diabetes 
mellitus.
1,13,14,18
   
 
South Africa suffers the burden of a number of aetiological agents such as hepatitis B 
infection which is five times more prevalent in people who are positive for human 
immunodeficiency virus (HIV) -infection compared to those who are HIV-negative;
19
 HIV 
infection is unfortunately particularly prevalent.  Liver fibrosis is more common in 
patients who are HIV-positive.
20
  Alcohol abuse is also a particular problem in South 
Africa.
21
  In addition, the prevalence of people classified as being overweight or obese in 
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South Africa is very high.
22
  South Africa also has seemingly unique risk factors for liver 
injury such as elevated dietary iron intake because of brewing traditional beer in iron 
drums.
23
  Kruger et al. demonstrated a high level of hepatic fibrosis in patients with 
NAFLD in the local population in Cape Town.
22
   
 
Assessing liver fibrosis 
Currently, the gold standard of fibrosis assessment is hepatic biopsy followed by 
histological examination, with most biochemical sera markers performing less well.
10
  
Liver biopsy, however, has a number of problems, such as its invasive nature, the 
problem of obtaining a representative sample, pain and the fact that it is not without 
risk (see Part B).  Very few health services can cope with the current, and anticipated 
increasing demand for liver biopsy.  This is particularly true in the resource-constrained 
health care system of South Africa.  Simply cutting costs by reducing staff or reducing 
costs across the board are not effective financial strategies.
24
  Efforts should be made to 
streamline healthcare, identify and resolve inefficiencies and provide novel and 
economical solutions, while maintaining and improving the quality of patient care.
24
  
Thus, a simple, accurate and reliable screening test that may exclude the need for 
biopsy is required.
10,13,15,18
 
 
Serum biomarkers 
Biomarker is a term that refers to any indicator that is measurable and can be used to 
indicate the presence or degree of injury.
25
  There are certain ideal characteristics such 
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as accuracy, precision, sensitivity, specificity, ease and cost-effectiveness of 
measurement and, in addition, it should guide clinical management.
14,18,25
  The ideal 
marker of liver fibrosis should be liver specific, should be unaffected by pathology 
affecting other systems, should measure some aspect of fibrosis, be of value as a 
screening tool and also be easy to measure.
14,18
  It should be readily available and its 
assay standardised.
26
  It should provide reliable prognostic information and should 
reflect the dynamic process involved in liver pathology with levels that correlate with 
the degree of injury so that it can be employed to monitor the response to treatment.
27
  
Prior to introduction into routine clinical practice, these characteristics of the biomarker 
under consideration should be determined.  No such marker exists.   
 
The case for prolidase 
Early fibrosis is characterized by collagen deposition, and the amino acid proline is a 
major component of collagen.  Thus with early liver damage, and subsequent scar 
tissue, more collagen will be deposited in the liver.  Prolidase is a peptidase which 
hydrolyses bonds involving proline which are resistant to degradation by most 
peptidases.
28
  Thus, with increased fibrosis and collagen deposition, there is an 
induction of prolidase, which is the enzyme that potentially will help to recycle collagen, 
and this shall be reflected in enhanced serum prolidase enzyme activity levels.
27,29
 
 
Recently, interest has been increasing in the use of the serum enzyme prolidase as a 
marker of hepatic fibrosis and work has been ongoing to investigate the relationship 
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between the degree of hepatic fibrosis and serum prolidase levels.
30
 This has been 
pursued because of the poor correlation of commonly used liver enzyme markers such 
as transaminases with the degree of fibrosis.
18
 
 
Prolidase consists of two subunits and requires Mn
2+
 as a co-factor for full activity.
28,31
   
It is found in many tissues and it is most prevalent in the kidney.
32,33
  Levels in plasma 
and serum are low.
32
  Its levels are unrelated to age, sex and do not appear to be 
increased by bone tumours either primary or secondary.
34
  There are reports that serum 
prolidase activity is increased in various pathologies characterised by fibrosis (see Part 
B).
35-39
 
 
Myara et al. measured plasma prolidase activity in a population of 338 hospitalised and 
outpatients with various diagnoses.  They established a log-gaussian distribution with a 
mean value of 900 ± 520 IU/L (2 SD).  Five out of 27 patients with cirrhosis had values in 
excess of 2 000 IU/L and a further three patients who had elevated levels had chronic 
liver disease.  Normal levels were found in patients with myocardial infarction, 
metabolic bone disease, acute hepatitis and cholelithiasis.  There was no correlation 
with common biochemical markers of liver injury namely transaminases, alkaline 
phosphatase, gammaglutamyl transferase, total bilirubin and albumin.
29
  Kayadibi et al. 
have shown that serum prolidase activity is a potential biomarker of liver fibrotic injury 
and can distinguish steatohepatitis from simple steatosis.
30
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Detailed methodology 
This shall be a prospective cohort study of adult patients at Groote Schuur hospital 
undergoing liver biopsy.  In collaboration with the Department of Anatomical Pathology, 
patients who are undergoing liver biopsy will be identified, and some of their sera held 
in the National Health Laboratory Service C17 Core laboratory at Groote Schuur Hospital 
stored at -80
o 
C until assessment.  The degree of liver fibrosis shall be determined and 
graded using established scoring systems based on histological examination by an 
experienced histopathologist blinded to the rest of the study.  The serum prolidase 
activity shall be assayed in the stored sera of these patients, with the results of the liver 
biopsies being blinded so that they are not available to the assayer.  The serum 
prolidase enzyme activity (SPEA) shall be plotted against the degree of liver fibrosis 
determined at biopsy.  The results will be analysed to assess whether serum prolidase is 
a marker of hepatic fibrosis, and whether the serum prolidase activity correlates with 
the degree of liver fibrosis.  The available liver function and other test results of these 
patients’ in-patient stay will be accessed.     
 
Measuring serum prolidase 
The most common way to measure SPEA is the colorimetric method of Chinard as 
modified by Myara et al.
29
  This involves a 24 hour pre-incubation of sera with Mn
2+
 
which results in a large increase in activity, although longer incubation times increase 
activity further (figure 1), followed by the addition of a substrate, glycyl-proline, which is 
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cleaved by the enzyme prolidase to yield glycine and proline.  Both the glycine and 
proline so released are free to react with ninhydrin but can be distinguished on the basis 
of the difference of the absorbance spectra of the chromogen formed.  The chromogen 
that results from proline’s reaction with ninhydrin is measured spectrophotometrically 
at 515nm against a serum blank.
32
    The equimolar amount of glycine-ninhydrin 
chromogen formed does not interfere at this wavelength (figure 2).  Work on 
streamlining the assay has continued and the 24 hour incubation step has been 
reduced.
27
  Intra-assay and inter-assay CVs of 3.8% and 9.0% respectively are reported.
34
  
Prolidase activity has been determined successfully in patients homozygous for 
prolidase deficiency using matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS),
40
 and a capill ry electrophoresis method with 
electrochemiluminescent detection has been published as well.
41
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Figure 1: Demonstration of increase in SPEA with incubation time.  Aliquots of the same 
sample were pre-incubated with Mn
2+
 for 24 or 48 hours prior to assay.  The x- values 
represent the incubation time, and the y-values, the SPEA. 
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Figure 2:  Three individual wavelength scans of 0.65 mmol/l solutions of glycine, proline 
and glycyl-proline respectively after reacting with ninhydrin.  This demonstrates that 
praline produces a peak in absorbance at 515 nm without interference from the 
chromogens produced by glycine or glycyl-proline. 
 
The linearity, CV and stability of prolidase will be examined as well as its ability to 
withstand freeze-thaw cycles using samples obtained from volunteers.  Values reported 
in the literature for prolidase activity vary widely and a comparison study shall be 
undertaken to assess the degree of transferability of results and whether reference 
intervals should be method specific.  In addition, as prolidase is present in erythrocyte, 
the possible interference of haemolysis shall be assessed.   Prolidase activity can be 
measured in cultured fibroblasts; an assessment of the feasibility shall be undertaken. 
 
Envisaged outputs/outcomes 
This study will investigate the feasibility of prolidase as a new marker in patients with 
hepatic disease. The work will be presented at the South African Society of Pathologists 
annual meeting, the annual conference of the Association for Clinical Biochemistry (UK) 
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and the American Association of Clinical Chemistry (USA).  The study will provide 
material for Dr Stanfliet’s MMed dissertation and will provide Dr Stanfliet with the 
opportunity to publish in a major peer-reviewed journal such as Journal of Clinical 
Pathology or Clinical Chemistry.  
 
Impact 
The project will establish a base of expertise in a new area of laboratory medicine as it 
applies to diagnostic clinical chemistry, in the Division of Chemical Pathology at the 
University of Cape Town.  Furthermore, the project will develop capacity in a new and 
emerging area that is under-researched in both the global, and, the South African 
context. 
Part B Literature Review 
 
This section is a literature review written as per the University’s guidelines copied below 
(see Appendix for the entir  set of University guidelines).  A single set of references is 
presented at the end of Part C to prevent repetition and unified numbering is used 
throughout this mini-dissertation. 
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Part B Literature review 
 
Evaluation of serum prolidase activity as a marker for liver 
fibrosis in suspected liver disease 
 
Summary   
Liver dysfunction is common, is anticipated to increase, is often silent and early 
treatment yields the promise of the best outcome (see Part A). This section describes 
current methods used in the diagnosis of hepatic injury, such as liver biopsy followed by 
histological examination, clinical imaging techniques, breath tests and current serum 
biomarkers.  Prolidase and diseases associated with alterations in its determined activity 
levels are detailed.  Gaps in the current knowledge base are highlighted and possible 
areas of future research are suggested.   
 
Search strategy and quality criteria 
The literature review was undertaken on PUBMED to identify articles relating to liver 
dysfunction, fibrosis, prolidase and the local South African situation.  The references of 
selected articles were also searched to identify relevant articles.  Review articles from 
the last five years were given preference.  Only articles published in English in peer-
reviewed journals were considered.  Articles describing the analytical methodology of 
measuring prolidase activity were specifically sought.   
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Assessing liver injury 
Liver disease is a global epidemic although, surprisingly, it hasn’t been identified as such 
by global agencies such as the World Health Organisation. Irrespective of the aetiology 
of liver disease, there is a final common pathway involving fibrosis, cirrhosis and further 
complications if the injury is overwhelming or continuous.  Consequently, there are a 
number of common means to assess the damage inflicted on the liver regardless of the 
aetiology. 
 
Liver biopsy 
Currently, the gold standard of fibrosis assessment is histological examination of hepatic 
biopsy specimens.
10,42,43
  Liver biopsy, however, is inherently invasive, and is associated 
with 1 - 5% rate of complications such as pain, hypotension, bleeding and the possibility 
of needle-track seeding of malignant cells in cancers.
42,44-46
  Rarely, fatalities have 
occurred at a quoted rate of 1 in 1 000 – 10 000.
45,47
  For these reasons, many patients 
find it unacceptable and r fuse to be biopsied.
17
  It is also difficult to standardise 
histological examination in much the same way that clinical chemistry tests are.
2,17
  
Furthermore, it is impractical to use biopsy to screen all patients with suspected liver 
disease or to use it to routinely follow their clinical course given the very high 
prevalence of liver injury, the potential risks involved with biopsy and the reality of 
constrained resources.
7,48
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Liver biopsy has a coefficient of variance (CV) of 55% with significant intra- and inter-
operator variability.
2
  A single blind percutaneous biopsy may miss established cirrhosis 
in 10 - 30% of cases.
17,44
  This is due to the sampling of a minute fraction (0.002%) of the 
liver at biopsy and the non-homogeneous nature of the pathology.
46-48
  A single liver 
biopsy provides a static picture that gives little information as to the dynamic waxing 
and waning process.
43
  Scoring methods used to assess the extent of hepatic fibrosis 
vary, and may give rise to different scores.
49-51
  In addition, it is argued that although 
fibrosis assessment is an important determinant of the stage of liver pathology, fibrosis 
and staging are not equivalent.
52
  Rossi et al. state that using a categorical scoring 
system to determine a continuous variable such as liver fibrosis is flawed, and that the 
assumption inherent in fibrosis scoring scales that fibrosis increases in a linear fashion 
between stages is incorrect.
26
 
 
As liver biopsy cannot be used as a screening tool, and there are difficulties using it to 
monitor the effectiveness of therapeutic interventions, other possibilities have been 
explored.  There are a number of non-invasive alternative analytical methods in current 
usage and they can be divided broadly into clinical imaging techniques, specialised tests 
of liver stiffness, breath tests and serum markers. Their strengths and shortcomings are 
discussed hereafter.   
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Non-invasive methods of assessing liver fibrosis 
Imaging modalities 
The current clinical imaging techniques can identify liver pathology but are unable to 
distinguish between the degrees of injury and may miss subtle damage.
13,30,47,49,53
  
Generally, current imaging techniques probably should be reserved for the assessment 
of portal hypertension or the presence of hepatocellular carcinoma in patients with 
established cirrhosis.
54
 
 
Ultrasound is the usual first-line imaging investigation.
55
  It can detect moderate fatty 
infiltration of the liver as fat attenuates the sound beam, but is relatively insensitive and 
cannot detect mild to moderate fibrosis.
14,45,48
  The success of ultrasound is also 
markedly operator-dependent.
48,55
  Computer tomography and magnetic resonance 
imaging (MRI) provide semi-quantitative information, may miss mild injury, cannot 
always differentiate between the degrees of damage and are subject to interference 
from conditions such as iron overload.
14,48,54
 
 
Transient elastography 
Transient elastography, a commercially patented technique, uses liver stiffness as a 
surrogate for liver fibrosis.  It employs a modified ultrasound probe to send vibrations 
through the liver and measures the rate of transmission of these waves which is a 
function of the stiffness of the tissue.
9
  It is rapid, can be done as an outpatient 
procedure, is painless and allows repeated examinations.
47
  It has been validated in liver 
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pathology secondary to various pathologies.
8
  It samples an area 100 times larger than 
does biopsy.
49
  Further, it appears to be operator independent if performed as per the 
manufacturer’s instructions even when comparing novice operators with minimal 
training with experienced operators.
8
  Generally, it performs excellently and may in time 
replace biopsy as the gold standard.
56
  However, it is unreliable in obese people, 
struggles in the presence of even minimal ascites, is very expensive and may not 
perform well at detecting minimal degrees of fibrosis.
8,15,45,56
   Invalid or uninterpretable 
results are found in nearly 20% of patients.
12
 
 
Breath tests 
There are a number of breath tests employing radio ctive isotope 
13
C–labels such as 
13
C-
methacetin.
16
  These generally perform well but require the use of radio-isotopes and 
specialized scintillation detectors and are not universally available.
45
  They are not in 
general clinical practice use. 
Serum biomarkers 
Serum is an attractive area for biomarker detection because of its low cost and 
accessibility.
7
  Individual commonly used biochemical screening tests such as alanine 
transaminase (ALT) levels correlate very weakly with the degree and activity of fibrosis 
seen at histology although they provide important information on other aspects of liver 
function.
6,14,26
  It is inaccurate to assume that all people with a normal ALT level are free 
of liver dysfunction.
14,15
 Surprisingly, data have shown that low levels of 
dehydroepiandrosterone-sulphate (DHEA-S) are seen in patients with non-alcoholic fatty 
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liver disease (NAFLD), and patients with DHEA-S levels above a certain cut-off are 
unlikely to have severe NAFLD.
7
 
 
A number of novel biomarkers of liver injury have been investigated such as procollagen 
type III amino terminal peptide (P3NP) and hyaluronan.
13,26,47,57
  P3NP is the most widely 
studied marker and its levels correlate with the degree of fibrosis.
47,58
  However, it can 
be elevated in pathology affecting other organs such as acromegaly, chronic pancreatitis 
and lung fibrosis.
57
  None of the other markers investigated to date appears sufficiently 
reliable for routine use.
56,57
  Most biomarkers that have been studied are good at 
detecting and quantifying moderate to severe fibrosis but miss subtle fibrotic injury or 
are unable to distinguish between mild degrees of fibrosis.
5,15
   
 
The use of test panels, such as liver function tests, has come under increasing scrutiny 
because of cost and concerns regarding unnecessary testing.
17
  However, ratios such as 
the aspartate transaminas  to platelet index (APRI) may offer many benefits not 
imparted by single tests.
2,7,20
  APRI has been extensively validated in hepatitis C infection 
and appears to be a reasonable low-cost test suitable for daily practice.
57
  The ratios in 
common usage generally use analytes that are routinely measured in patients with liver 
disease.
45
  However, many of the various models are unable to classify correctly almost 
25-50% of patients or use patented multi-variable derivatives that require the payment 
of royalties.
15,17
  Currently, most serum models are used in parallel with, rather than as 
replacement for liver biopsy.
26
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Prolidase 
Early fibrosis is characterised by the deposition of collagen which is a protein that is 
particularly rich in the amino acid proline.
27,28
  There is even evidence that the proline 
component of collagen increases slightly with increasing fibrosis.
29
  Dipeptides where 
proline or hydroxyproline constitutes the carboxy-terminal amino acid are resistant to 
cleavage by non-specific peptidases, and require a dedicated peptidase known as 
prolidase (peptidase D, imidodipeptidase, proline dipeptidase, aminoacyl-L-proline 
hydrolase; EC 3.4.13.9) which cleaves such dipeptides which are mainly collagen 
breakdown products.
32,59-63
  This allows up to 90% of proline to be  recycled in collagen 
biosynthesis.
32,61,63
  In periods of sustained collagen deposition such as fibrosis, 
prolidase may become the rate-limiting step.
27,63,64
  Prolidase activity is induced in 
settings of increased fibrosis and this may be reflected in increased serum prolidase 
enzyme activity (SPEA) levels.
29,33,65
  The exact mechanism of this induction is not clear 
but it is theorised that type 1 collagen in the extra-cellular matrix binds to and 
stimulates prolidase activity via cell surface β1-integrin receptors.
65
  Further, insulin-like 
growth factor-1 (IGF-1) can stimulate collagen production on binding the IGF-1 receptor 
and via the same mechanism can stimulate prolidase activity.
64
 
   
The characteristics of prolidase 
Prolidase, a 493 amino acid polypeptide, was first identified in 1923.
32
  It is a 110 kDa 
homodimer.
31,66,67
  The 15-exon gene that encodes a 2.2 kb mRNA product is located on 
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chromosome 19p13.2 and spans a region > 200 kb of DNA.
63,68
  The protein product 
undergoes post-translational modification via glycosylation and phosphorylation.
28
  Its 
three-dimensional structure has been characterized (Figure 1).  It is found in many 
tissues and it is most abundant in the kidney and erythrocytes.
32,33
   
 
Figure 1: Crystal structure of human prolidase (http://www.ncbi.nlm.nih.gov/sites/entrez#) 
Studies have shown that prolidase activity is dependent on Mn
2+
,  temperature and pH, 
with a pH optimum of 8.0 - 9.0 and a temperature optimum of 37 
o
C.
60-62
  Colchicine 
increased the activity when glycyl-proline but not valyl-proline was used as a 
substrate.
31
  The reason for this observation is not clear.  Prolidase is inhibited by 
various substrates including nickel and the product of its reaction, proline, in a 
competitive manner. 
66,69
   
 
The catalytic mechanism requires that the proline residue of the substrate is enfolded in 
a hydrophobic pocket, consisting of six strands with a beta configuration, which ensures 
the correct spatial orientation of the peptide bond.
60
  Five of these strands bind metal 
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ions.
60
  A water molecule becomes polarized by interaction with manganese and/or 
sodium ions, although cobalt and zinc metal ions can also be used, and is positioned for 
nucleophilic attack on the carbonyl carbon of the peptide bond.
66,70
  A conserved 
glutamate temporarily extracts a proton from this nucleophile.  A histidine residue and 
one of the metal ions stabilize the intermediate produced.  Finally, the glutamate 
donates the proton it captured from the nucleophile to the amine leaving group, 
thereby converting the intermediate to the final product.
28
 
 
Prolidase deficiency 
The congenital absence of prolidase (prolidase deficiency (PD)) was first reported 40 
years ago.
32
  The demonstration of reduced prolidase enzyme activity was published in 
1974.
71
  To date, only 60 or so case reports have been published, although its apparent 
rarity might reflect unawareness on the part of physicians.
28,29,32
  PD is inherited in an 
autosomal recessive manner.
32
  Mutations in the highly conserved catalytic region 
appear to be responsible although the pathophysiology remains poorly understood.
28
  
The phenotype is variable but skin ulceration of the lower limbs is the hallmark,
72,73
 
along with mental retardation and recurrent respiratory infections.
60
  The mental 
retardation may arise from cerebral microthrombi identified on MRI in patients with 
PD.
74
  There is a characteristic facies with frontal bossing, a low hairline, hypertelorism, 
proptosis and saddle-nose deformity.
32,73
  Immune abnormalities include recurrent 
infections, defective wound healing, increased serum immunoglobulin and low levels of 
complement 1q, which contains approximately 25% proline.
28,32
  The clinical 
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heterogeneity implies that environmental factors are important, and some patients with 
documented genotypic mutations are apparently asymptomatic.
67,75
 
 
The biochemical picture is of severe imididopeptiduria.
75
  Chromatographic examination 
of the urine reveals high levels of glycyl-proline and glycyl-hydroxyproline, and reduced 
enzyme activity can be shown in leucocytes or fibroblasts.
28,32
  There is no specific 
treatment, but Mn
2+
 and vitamin C supplementation have been used with varying 
success, and blood transfusions, apharesis and corticosteroids have also been 
employed.
28,71,76
  There is no experimental animal model to further the study of PD.
77
   
 
Other uses for prolidase 
Prolidase antagonises the toxic effects of organophosphorous compounds, and has been 
investigated by the military defence industry.
78
  It is used in the food industry to reduce 
bitterness in cheese.
28
  High levels of prolidase are found in melanoma and breast 
cancer cells and there is research to produce a chemotherapeutic prodrug, that is a 
proline analogue of melphalan, that requires prolidase to cleave it to release the active 
metabolite, thereby allowing for targeted drug delivery.
28,79,80
 
Prolidase as a marker of hepatic fibrosis 
The biological plausibility of using serum prolidase as a marker of liver fibrosis has been 
established in rat models.
4,27,30,59,81
  SPEA has been reported as being significantly higher 
in rats that underwent irreversible bile duct ligation compared with those who had a 
sham operation or controls (p < 0.001).
27
  Following irreversible liver damage, the liver 
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collagen content, histological grading of fibrosis and SPEA all increased together, rising 
to a peak, before declining in synchrony once cirrhosis was evident.
27,58,59
  However, 
Zuyderhoudt et al. failed to demonstrate an association between plasma prolidase and 
rat hepatic fibrosis and ascribed increases in plasma prolidase to leakage from damaged 
liver cells rather than induction of its activity because of fibrosis.
82
 
 
There are few clinical studies examining SPEA levels in humans with liver disease.  Myara 
et al. measured plasma prolidase activity in a population of patients with liver disease 
and other disorders.
29
  Plasma prolidase activity was compared with the degree of liver 
fibrosis at biopsy in 13 patients in this series and the authors concluded that there was 
no correlation between the two.
29
  The statistical handling of the data in this study is a 
major weakness.  A reference distribution that is log-gaussian would not be symmetrical 
about the mean when back transformed.  In addition, the population used to establish 
the reference interval included patients with liver disease, whereas patients with overt 
and occult disease should be excluded during the establishment of a reference 
interval.
83
  Therefore, this published reference interval needs to be viewed 
circumspectly, but these values are still referred to in other studies.
30
  The authors 
speculated that, as prolidase activity was elevated only in some and not all of the 
patients with cirrhosis, that enzyme activity varied with the stage of the disease, 
increasing in the early stages and declining as cirrhosis advanced.
29
  Importantly, it is not 
clear what criteria were used to confirm liver disease except for 13 patients who were 
explicitly stated to have undergone a biopsy. 
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Brosset et al. found a correlation between the findings at biopsy and plasma prolidase in 
a study of 53 adult “alcoholic” patients with alcohol intake > 60 g/day, but could not use 
plasma prolidase to distinguish between early fibrosis and more severe pathology.
81
  
There are a number of limitations to this study which makes it quite difficult to 
generalise the findings.  The means by which patients were identified and selected were 
not described.  Further, although patients were described as “alcoholic”, there was no 
indication as to how this diagnostic label was reached, or how the quoted daily alcohol 
consumption was determined or confirmed. 
 
Recently, Kayadibi et al. performed a prospective study which enrolled 54 patients and 
17 healthy controls and used SPEA to distinguish successfully between steatosis and 
steatohepatitis.
30
  Liver biopsy was the gold standard used in the assessment of NAFLD.  
This study showed a positive correlation between raised SPEA and liver fibrosis (p < 
0.001) and a negative predictive value of 92% for fibrosis at a SPEA cut-off value of 1 295 
IU/L.  Significantly, none of the patients had severe fibrosis at biopsy.  Other 
confounding variables such as obesity and other causes of fibrosis were not accounted 
for.
7
 
 
Horoz et al. showed an association between SPEA and the degree of fibrosis in a 
prospective study in patients with non-alcoholic steatohepatitis (NASH).
84
  Levels were 
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significantly higher in the 36 consecutive patients with NASH than in the 29 controls (p = 
0.016).  There was no patient documented with cirrhosis in this study.   
 
Prolidase levels in pathology of non-hepatic origin 
Collagen is distributed widely in the body and one concern is whether SPEA levels are 
altered in other situations of increased collagen deposition and/or breakdown.  One 
such circumstance is osteoporosis, as type I collagen comprises ~90% of the bone matrix 
and post-menopausal osteoporosis is associated with increased degradation of the 
organic matrix of bone.
34
  A study of post-menopausal women with osteoporosis found 
no correlation between SPEA and bone mineral density (BMD), measured with dual 
energy X-ray absorptiometry (p > 0.05).
34
  This finding has been replicated.
85
  SPEA is 
unrelated to age and sex, and does not appear to be increased by bone tumours of 
either primary or secondary origin.
34
  There is no increase in SPEA in uraemic bone 
disease.  A study involving 44 participants found that end-stage renal disease was not 
associated with increased levels of serum prolidase.
33
  Normal levels have been 
reported in patients with acute hepatitis and cholelithiasis.
29
  
 
Aslan et al. reported that SPEA levels were significantly higher in patients with H. pylori 
than in those without infection in patients investigated for non-ulcer dyspepsia.
35
  The 
authors speculated that this might reflect increased gastric fibrosis caused by chronic 
infection.  There are reports that SPEA may be increased in patients with asthma 
managed with theophylline, in hypertensive patients and in breast cancer.
34,38,86
  In type 
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2 diabetes mellitus (T2DM), vascular basement membrane is characterised by the 
presence of increased connective tissue.
87
  Reports from patients with T2DM are 
conflicting with both elevated and reduced levels of SPEA being demonstrated.
34,87
  
Elevated levels have been shown in fibroblasts obtained from keloid tissue.
88
  A recent 
report showed elevated levels of prolidase activity in amniotic fluid from patients with 
neural tube defects.
89
  Intra-uterine growth retardation is postulated to result from 
increased extra-cellular matrix turnover in the placenta resulting in impedence to 
vessels and relative hypoxia to the foetus.
39
  Toy et al. demonstrated elevated maternal 
SPEA levels in a cross-sectional study in mothers with infants who had foetal growth 
retardation.
39
   Tuberculosis (TB) is still an unfortunately common condition in the 
Western Cape province of South Africa with significant morbidity and mortality.  The 
assessment of whether pleural effusions are tuberculous in origin remains invasive and 
a significant part of laboratories’ workload in the developing world.  Both serum and 
pleural fluid prolidase have been reported as being significantly elevated in pleural 
effusions of tuberculous origin compared with other aetiologies in a cross-sectional 
study.
90
 
 
Asthma is a chronic airway inflammatory condition, and lower SPEA levels have been 
described in children with asthma compared with healthy controls.
37
  The authors 
speculated that this represented established fibrosis with little collagen turnover.
37
  
Prolidase deficiency has been reported in a few case reports of patients with systemic 
lupus erythematosus (SLE) and there are suggestions that it may impart increased risk of 
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developing SLE.
68,74,91,92
  Galicka et al. documented low levels of prolidase activity in 
cultured fibroblasts from a patient with mild osteogenesis imperfecta.
64
   
 
A Turkish group has published a number of studies documenting increased SPEA 
associated with evidence of increased oxidative stress in diverse clinicopathological 
conditions.
35,37,39,89
  The significance of these data is unknown. 
 
Measuring and reporting SPEA 
The most common way to measure SPEA is the colorimetric method of Chinard as 
modified by Myara et al.,
29
 but there have been a number of refinements reported and 
used in the evaluation of SPEA.  This has resulted in a wide range of values reported in 
the literature for SPEA ranging from mean values of 40 to 1 500 IU/L (see table 
1).
27,30,34,35,37
  What is much harder to explain is the discrepancy in values obtained using 
the same methodology from what appears to be the same group in Turkey (Table 
1).
35,37,84,87
  A further concern is the methods employed to represent the data.  As 
highlighted earlier, some of the statistical handling of the data and the production of 
reference intervals are not acceptable.  Reporting of data has also been done with mean 
± SD although there is no evidence that the reference distribution for SPEA is gaussian. 
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Method SPEA result 
reported (IU/L) 
Reference 
Classical method described by Myara with 24 h incubation of 
serum with 2.5 mM Mn
2+
 in a 1 in 6 serum dilution,  Used 94 mM 
glycyl-proline substrate concentration 
900 (520)  
(mean (SD))  
27 
Used a higher concentration of Mn
2+
 than Myara, also added 
glutathione to the sample incubation mixture.  Pre-incubated for 
only 3 h.  Used much higher gly-pro (144mM) substrate 
concentration 
972 (862 - 1 
122) (median 
(IQR)) 
29 
Serum diluted 40-fold with 2.5 mM Mn
2+
.  Low levels of gly-pro 
used (30mM).  3 h incubation 
80.7 (16) 
(mean (SD)) 
84 
Serum diluted 40-fold with 2.5 mM Mn
2+
.  Low levels of gly-pro 
used (30mM).  2 h incubation 
1 613.84  
(607.25) (mean 
(SD))  
34 
Serum diluted 40-fold with 2.5 mM Mn
2+
.  Low levels of gly-pro 
used (30mM).  2 h incubation 
39.18 (5.4) 
(mean (SD)) 
35 
Serum diluted 40-fold with 2.5 mM Mn
2+
.  Low levels of gly-pro 
used (30mM).  2 h incubation 
1 408 (162) 
(mean (SD)) 
37 
Serum diluted 40-fold with 2.5 mM Mn
2+
.  Low levels of gly-pro 
used (30mM).  2 h incubation 
53.3 (2.2) 
(mean (SEM)) 
87 
Table 1: Description of the differences in the methodology employed, results obtained 
and the reporting thereof.  IQR: interquartile range; mM: millimoles/litre; h: hour; SD: 
standard deviation; SEM: standard error of the mean   
 
Future research 
It is evident from the above literature review that a number of basic issues need to be 
addressed in the prolidase field.  Firstly, evidence of the biological variation of SPEA is 
required.  This would be aid in the assessment as to the potential usefulness of 
reference intervals.
83
  Knowledge of biological variation would also guide knowledge as 
to the required analytical CV which is often targeted at a value half the biological CV to 
minimize the noise added by the analytical technique to the width of the reference 
interval.  Further, information on biological variation is required when calculating 
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reference change values which would be useful if SPEA were employed in monitoring.
93
  
There is no information on SPEA levels or characteristics in the paediatric setting.  
Information on ethnic differences, influence of diet, circadian rhythm if any, and 
preanalytical factors is lacking.  There exists an urgent need to establish a reference 
interval using appropriate methods which may well be method-specific.  Most 
biomarkers of liver fibrosis have been studied in cross-sectional studies and longitudinal 
studies are needed to provide data as their role in establishing prognosis, monitoring 
disease activity and response to therapy.
12,15,16
  The reported increase in SPEA in 
patients with TB pleural effusions needs to be investigated further, given the high 
prevalence of TB in the Western Cape.  Levels in patients with TB without pleural 
effusions should be investigated.  In summary, the investigation of SPEA is in its infancy. 
 
Any research on a potential biomarker requires a reference standard against which to 
assess the diagnostic performance of the measurand in question.  In liver dysfunction, 
this remains the liver biopsy which is an imperfect standard as discussed earlier.
12
  Its 
very limitations may result in a falsely low assessment of the diagnostic accuracy of a 
new method to measure liver fibrosis, even if that method were perfectly sensitive and 
specific.
53
  Limiting the sample to patients undergoing liver biopsy may introduce a 
selection bias as these patients have more severe pathology, which might limit the 
generalisation of any findings.  However, it is questionable whether it would be ethical 
to biopsy healthy people, given the real, albeit negligible, risks involved.  Transient 
elastography may overcome this issue. 
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Part C Manuscript 
This part is a stand-alone manuscript that is written to be included in a relevant peer-
reviewed journal in accordance with the journal’s requirements as set out in the 
“Instructions for Authors”.  This article is written for the journal, Annals of Clinical 
Biochemistry, in accordance with their requirements (Part D).  The manuscript is 
therefore laid out with an abstract, introduction, methods, results, discussion and the 
tables and figures thereafter rather than being included in the text.  As the journal has a 
limit as to the number of tables and figures that may be presented, a supplementary 
data section follows that includes relevant supplemental figures and tables 
(Supplementary data).  However, there is no separate list of references for this section 
and the common reference list is to be consulted.  Unfortunately, as this is a separate 
manuscript, some of the previous discussion from Part A and B will be repeated here.  
This manuscript is written in accordance with the Reporting studies of diagnostic 
accuracy (STARD) guidelines (page 61. 62).
94
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Part C The sensitivity and specificity of serum prolidase 
activity as a marker for liver fibrosis in suspected liver 
disease 
 
Liver disease elevates serum prolidase levels 
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Abstract 
Background  Liver dysfunction is common and often unrecognised.  Liver biopsy is the 
gold standard in the assessment of liver fibrosis, but has disadvantages.  Many viable 
options have been investigated.  We assessed the diagnostic accuracy of serum 
prolidase enzyme activity (SPEA) in predicting the presence and degree of liver fibrosis, 
as compared with liver biopsy. 
Methods   We undertook a prospective case control study.  38 outpatients without 
apparent liver illness and 20 patients with liver pathology scheduled to undergo liver 
biopsy had their SPEA levels measured.  We evaluated a SPEA assay for linearity, 
imprecision, stability of the measurand and the effect of haemolysis.  We used the data 
from the control group to establish a reference interval. 
Results  The SPEA assay is linear and has reasonable imprecision.  It is affected by 
haemolysis and freeze-thaw cycles should be avoided.  A reference interval of 22 - 504 
IU/l was obtained.  Patients undergoing liver biopsy had higher SPEA levels (361 (268) 
IU/L [median (interquartile range)]) compared with controls (169 (160) (p < 0.001)).  A 
SPEA cut-off value of 200 IU/l yielded a sensitivity of 89%, specificity of 59%, an odds 
ratio of 11.5, negative predictive value of 92% and a positive predictive value of 50%. 
Conclusions   Higher SPEA levels in patients undergoing liver biopsies compared with 
controls may reflect the presence of liver fibrosis.  SPEA levels could not be used to 
stage the degree of fibrosis.  The utility of SPEA as a biomarker of liver injury should be 
investigated further. 
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Introduction 
Liver disease is common,
1,13
 likely to increase in prevalence,
1
  but often silent with many 
patients developing advanced disease.
18
  Ongoing injury may result in fibrosis which is 
associated with significant morbidity and mortality but is treatable even when 
advanced.
4,11
   
 
Liver biopsy followed by histological examination is the accepted reference standard in 
the investigation of patients with suspected liver disease.
10,43
  However, it has multiple 
potential problems owing to its invasive nature,
42
  and it may not be as accurate as often 
believed.
2,17,47,48
  Other methods that have been investigated such as clinical imaging 
techniques,
13,14,30,48
  measures of liver stiffness such as transient elastography,
9,11,49,95
 
individual serum biomarkers and combinations thereof all have various 
shortcomings.
2,11,13,14,18,42,47,48,96
   
 
Prolidase is a cytosolic enzyme that cleaves collagen breakdown products,
32
 is important 
in collagen recycling and is the rate limiting step in fibrosis;
64
 moreover, its activity is 
induced in periods of fibrosis.
29,64
  Levels in the serum are low,
32
 but experiments that 
induced irreversible liver injury in rats, showed a strong correlation between the degree 
of resulting fibrosis and the serum prolidase enzyme activity (SPEA) levels.
4,27,59
   
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 44 
Although a number of cross-sectional studies have measured prolidase in various clinical 
situations such as gastritis,
35
 asthma,
37
 inter-uterine growth retardation,
39
 left 
ventricular hypertrophy,
38
 osteoporosis,
85,87
 bone disease seen in chronic kidney 
disease,
33
 tuberculosis,
90
 breast cancer,
86
 and neural tube defects,
89
 there is a paucity of 
studies in the setting of its main indication, liver fibrosis.  Myara et al. measured plasma 
prolidase activity in 338 hospitalised and outpatient French patients with various 
disorders.
29
   The authors found elevated levels of plasma prolidase in 5 out of 27 
patients known to have cirrhosis.  However, there was no correlation between plasma 
prolidase activity and the degree of liver fibrosis determined at liver biopsy in 13 
patients in this study.  Brosset et al. measured plasma prolidase enzyme activity and 
compared these to the liver histology results on 53 adult patients with alcoholism who 
had alcohol intakes in excess of 60 g/day.  They found that levels of SPEA correlated 
with both cirrhosis and alcoholic hepatitis, but could not use it to distinguish between 
early fibrosis and more severe pathology.
81
  A recent prospective study of 54 patients 
and 17 healthy controls used SPEA to distinguish between steatosis and steatohepatitis 
(NASH) in patients with non- alcoholic fatty liver disease (NAFLD) (p < 0.001).
30
  Horoz et 
al. showed that SPEA levels were significantly higher in 36 consecutive patients with 
NASH, compared with controls (p = 0.016).
84
  Therefore, we undertook a study to 
ascertain the diagnostic accuracy of SPEA compared with liver biopsy and whether it 
could be used as a biomarker to assess the potential presence and degree of liver 
fibrosis in our local setting.  
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Methods and Materials 
The study was approved by the University of Cape Town’s Research Ethics Committee.  
Written informed consent to be included in the study was obtained from all participants 
undergoing liver biopsy. 
 
A total of 64 patients were enrolled in the study, which included 28 people undergoing 
liver biopsy examination at Groote Schuur Hospital, a tertiary hospital in Cape Town, 
South Africa.  All inpatients scheduled to have liver biopsy from October 2009 to August 
2010 were considered.  Patients were excluded if the liver biopsy was cancelled or was 
done as an outpatient procedure. Samples were reject d if patients did not provide 
informed consent (8 of the 28 patients were thus excluded).  Serum and liver biopsy 
samples were analysed on the patients undergoing biopsy.  A control group of serum 
samples from 38 outpatients at the same hospital were used (Figure 1 and Table1).
94
  
These were patients who were attending hospital for non-liver related pathology and 
did not have liver related tests requested.  Demographic data to ensure that the 
samples were from adults were checked, but no other data were captured. 
 
Prolidase Assay 
Serum samples were stored at -80
o 
C before being analysed using a well-described 
spectrophotometric method based on the reaction of proline with Chinard’s reagent.
29
  
5 μl of serum was incubated for 2 h with 15 μl 5 mmol/l MnCl2 in 100 mmol/l Tris HCl 
(pH 8.0) in a 37
o 
C water bath.   Thereafter, 60 μl 100 mmol/l glycyl-proline (Sigma-
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Aldrich), 80 μl 100 mmol/l Tris (pH 8.0) and 40 μl water was added and the mixture was 
incubated for 30 min in a 37
o 
C water bath.  The reaction was stopped by the addition of 
100 μl 20% (w/v) trichloroacetic acid (TCA).  The mixture was centrifuged for 5 min and 
200 μl supernatant fluid was mixed with 400 μl glacial acetic acid and 400 μl Chinard’s 
reagent (2.5 g of ninhydrin dissolved at 70
o 
C in 60 ml glacial acetic acid, 23.7 mL water 
and 16.3 ml 85% orthophosphoric acid (d = 1.7)) and heated for 10 min at 90
o 
C.  Colour 
development at 515 nm was read against a blank treated similarly except for the 
addition of TCA prior to substrate.  Proline concentration was calculated using a proline 
standard curve of increasing concentrations of proline (Sigma Aldrich) in 6.7 % (w/v) 
TCA.  SPEA levels were reported as µmol proline formed per min per litre serum (IU/l).  
Quality control was performed via frozen aliquots of a single serum analysed in each 
run.  This colorimetric method has a very low coefficient of variation.
30
  The person 
performing the SPEA assay (JCS) was blinded as to the results of the liver biopsy.   
 
Methods used to investigate prolidase assay 
The linearity of the assay as well as an assessment of the stability of SPEA at room 
temperature, freezing and with repeated freeze-thaw cycles were performed.  Intra-
assay CV was performed by measuring a pooled serum sample 10 times.  The effect of 
haemolysis was assessed on a pooled serum sample using a published modified osmotic 
shock method.
97
  Briefly, a haemolysate was made by centrifuging whole blood obtained 
from a volunteer and thereafter the plasma was removed.  The red cells were washed 
five times with equal volume normal saline, and then stored at -20
0 
C overnight with an 
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equal volume of distilled water.  This was then centrifuged and the haemoglobin (Hb) in 
the supernatant measured.  A range of haemolysates were then prepared using 
dilutions of this stock solution in saline to provide a range of Hb 0 - 100 g/l in increments 
of 5 g/l.  100 μl of increasing haemolysate (100 μl saline was used as a blank) was added 
to 900 μl pooled serum.  In addition, to ascertain the comparability of published 
methods, 10 pooled serum samples were analysed using two well-described assays of 
Myara and Kayadibi and a comparison was done.
29,30
  A reference distribution was 
established using the control samples (n = 38).   
 
Cultured fibroblasts 
5 cell lines (n = 10) of skin fibroblasts used as controls in routine investigations and that 
were close to their expiry date and due to be discardaed were used.   The fibroblasts 
were grown in duplicate under standard conditions (see Appendix).  Briefly, the 
fibrblasts were grown in Dulbecco’s modified eagle’s medium and foetal calf serum with 
added glutamine and antibiotics.  They underwent two passages of tryptinisation before 
being stored.  Confluent fibroblasts were harvested and washed, before being 
resuspended in 0.3 mL 50 mmol/l Tris-HCl (pH 7.8).  The fibroblasts were sonicated for 
three cycles of 5 bursts each at 30% power and duty cycle, and placed on ice between 
cycles. The supernatant was used for protein determination and 0.1 ml supernatant 
fluid was pre-incubated with 0.1 ml 0.05 mmol/l Tris HCL (pH 7.8) containing 2 mmol/l 
MnCl2 for 2 h at 37
o
 C before proceeding using the method described above. 
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Histopathological assessment of liver biopsy  
The liver biopsies were stained with haematoxylin and eosin, and further slides were 
made with bile sirius red stains.  The degree of fibrosis at biopsy was assessed using a 
well-characterised scoring system by one pathologist who was blinded to the results of 
SPEA analysis but who had access to the patient’s records if required (ML).
50
   
 
Statistical analysis 
Statistical analysis was undertaken on Microsoft Excel and Statistica 9.0.  Data became 
gaussianly distributed after being transformed by taking square roots.  The F-test of 
variance was used on the square-root transformed data to establish that variances were 
equal, and then Student’s unpaired t-test assuming equal variances was used.  Back-
transformed data are shown and box-and-whiskers plots drawn.  P < 0.05 was taken as 
indicative of statistical significance.   
 
Results 
Prolidase assay  
Linearity of the prolidase assay was demonstrated by assaying a serum sample neat and 
at increasing dilutions (Supplemental data Figure 1S).  This agreed with previous 
reports.
29
  SPEA activity appeared stable at room temperature for one week and at -20
o 
C for two months, but repeated freezing and thawing resulted in decreases in activity, 
and showed a decrease of 15% with the first cycle (Figure 2 & supplemenntal data 
Figure 2S & 3S).  We obtained an intra-assay co-efficient of variance (CV) of 11% which 
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was higher than that reported by Kayadibi et al.
30
  Haemolysis was a significant 
interferant in the prolidase assay and even low levels of haemolysis affected the 
obtained results (Figure 3).  Haemolysed samples should be rejected.  Comparison of 
SPEA levels obtained using the methods described by Myara and Kayadibi provided 
different results which were not comparable (R
2
 = 0.38) (Figure 4, supplemental data 
Figure 4S). 
 
Reference interval  
The SPEA value for one participant in the control group was removed as an obvious 
outlier.  The reference distribution became gaussian when the square root of the data 
was taken (Figure 5).  A mean value of 174 IU/l was established with a range of 22 – 504 
(mean ± 2SD) when the data were back-transformed.   
 
Fibroblast assay 
The 5 fibroblast cell lines yielded prolidase activity of 342 (43) nmol/min/mg protein 
(mean (SD)).  This is somewhat higher than the results reported by Galicka et al.
64
 
 
Liver biopsy and SPEA assay 
No adverse events were reported in any of the patients.  The characteristics of the 
patients who underwent liver biopsy are shown (Table 2).  Some patients did not have 
all tests performed during this admission.  In those cases, all available data were 
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analysed.  The fibrosis assessment at biopsy and accompanying SPEA are shown (Table 
2, supplemental data Figure 6S).   
 
Two patients tested positive for hepatitis B virus (HBV) infection and two for human 
immunodeficiency virus (HIV) infection.  Two further patients tested positive for two 
infectious agents: one for HBV and HIV, and the other for HIV and syphilis.  Thus, in total 
six (30%) of patients who had a liver biopsy tested positive for HIV, hepatitis B and/or 
syphilis.  No patient returned a positive test for hepatitis A or C infection.   
 
The patients who underwent liver biopsy had higher SPEA levels than the controls that 
did not (p < 0.001) (Figure 6).  SPEA values were: control group 166 IU/L (22-504) (mean 
(mean ± 2SD), the entire fibrosis group 376 (p < 0.001 vs. controls), minimal fibrosis 
group 392 (p < 0.001 vs. controls), extensive fibrosis group 335 (p < 0.001 vs. controls).  
There was no significant difference in SPEA levels between the groups with minimal and 
extensive fibrosis (p = 0.59) (Figure 11).  
 
Receiver operating characteristics curve analysis revealed an optimum cut-off of 200 
IU/L for the detection of fibrosis (Figure 12).  This SPEA cut-off value yielded a sensitivity 
of 89%, specificity of 59% and a diagnostic odds ratio of 11.5.  This assay had a negative 
predictive value (NPV) of 92% and a positive predictive value (PPV) of 50%.  Area under 
the ROC curve was 0.96.  If these results were translated into a screening test in a 
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general unselected population, then using a quoted population prevalence of liver 
fibrosis of 2.8%,
11
  this translates into a NPV of 99.5% and a PPV of 5.9% (Table 3).  
 
Discussion 
This study demonstrated that SPEA levels were significantly higher in patients 
undergoing liver biopsy than in control patients who were attending outpatients and 
assumed to be free of liver pathology.  The lack of liver biopsies on the group of controls 
is problematic, but ethically it is difficult to justify biopsy of apparently healthy people 
given the real, albeit small, risks involved.
42
  Therefore, there may be individuals in the 
control group with liver fibrosis.  If this is the case, this would serve to reduce the 
apparent discriminatory power of SPEA analysis in this study.  Setting this study in a 
tertiary institution introduces spectrum bias that may make the findings less 
generalisable.
49
   
 
We established that the reference distribution is square root-gaussian in appearance 
and using a group of outpatients established a reference interval that is different to that 
previously published.
29
  Myara et al. established a reference interval from a group of 
patients many of whom had established liver disease and it is not clear whether 
appropriate statistical techniques were employed in generating the reference interval;
29
 
this would not be an acceptable means to establish reference intervals today.
83
  The use 
of outpatients may be questioned but has been proposed as a proxy of healthy people 
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and has been used to establish reference intervals in other studies.
98
  We have shown 
that results are not interchangeable between methods and therefore suggest that 
reference intervals are method dependent. 
 
Fibrosis is often, but not inevitably, found in chronic liver injury and this may reflect the 
apparent lack of resolving power of SPEA analysis when examining the sensitivity, 
specificity and related data.
18
  At a cut-off SPEA value of 200 IU/l a negative predictive 
value of 92% can be obtained but is at the expense of multiple false positives as the 
specificity is 59%.  This mirrors the findings of other researchers.
30
  A negative likelihood 
ratio at this cut-off is 0.19 which is above the suggested value < 0.1 for an excellent 
test.
49
  Liver biopsy is the current gold standard but it has certain limitations that should 
be considered when assessing the diagnostic accuracy of a new marker.
42,53
  The use of 
transient elastography as the reference method may obviate this problem in future 
studies. 
 
There was no significant difference in SPEA in the group with minimal compared with 
extensive fibrosis as determined by liver biopsy.  This is apparently at odds with the 
results reported by Kayadibi et al. but they had no patients with moderate to severe 
fibrosis in their study.
30
  However, there appears to be an increase in SPEA with mild-
moderate fibrosis, with a reduction once fibrosis becomes more severe. This trend is not 
statistically significant but replicates other published data.
27,37,59
  It has been suggested 
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that more advanced fibrosis is characterised by a slower turn-over of collagen than 
states of moderate fibrosis and this may lessen the induction of prolidase activity.
29
 
 
This study demonstrated that SPEA reportable range is linear, has a reasonable CV for a 
manual test and is quite stable but that freeze-thaw cycles should be avoided.  The 
values that were obtained for SPEA in this study were lower than those reported in 
several other studies but this appears to be due to differences produced by the 
analytical methods used.
29,30,34,37
    There is no agreed reference method or standard 
reference material available.   
 
This study has shown that haemolysis is a positive interferant in SPEA analysis because 
prolidase levels are high in erythrocytes.  No haemolysed samples were used in this 
study.  It is not clear how any haemolysed samples, if any, were handled in previous 
studies.
29,30,34,37
   
 
Cultured fibroblast prolidase activity was reduced in one case report of a family with 
osteogenesis imperfecta;
64
 expression of prolidase in fibroblast cultures should be more 
thoroughly investigated.  To this end this paper has demonstrated the feasibility of 
measuring prolidase activity under local conditions, and provided values that may be of 
use for other researchers. 
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There is as yet little knowledge as to the biology of SPEA.  Future areas of research 
include further diagnostic accuracy studies, SPEA levels in various clinicopathological 
conditions such as Paget’s disease and an examination of the biological variation in 
healthy people including pregnant women and children.  In view of the HIV epidemic in 
South Africa, and reports that liver fibrosis is more common in people who are infected 
with HIV, SPEA should be investigated in this setting.
20
  Tuberculosis remains a 
significant source of morbidity and pathology locally and early promising reports that 
SPEA can be used to distinguish correctly pleural effusions of tuberculous from non-
tuberculous origin should be investigated further.
90
  As yet, we can find no published 
longitudinal studies looking at the clinical outcomes with prolidase. 
 
There are issues with the current assay that should be addressed.  Although the turn-
around time of the prolidase analysis has improved dramatically with a reduction in the 
length of time for the pre-incubation step, this remains extended at two hours and 
would not fit modern work flow practices and expectations for a routine screening test.  
Further refinements of the assay have been described which should be investigated.
27
  
Further evolution of the assay may involve the use of an artificial substrate which, when 
cleaved by prolidase, produces a chromogen directly without the need for further 
manipulation.  The role of other well-known possible interferants, including bilirubin 
which interferes in numerous assays and may be increased in the population of interest, 
remains to be elucidated. 
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Tables and figures 
Tables 
 
 
Category Mean (SD) Reference interval 
Sex male/female 7/13  
Age (years) 39.9 (16.0)  
AST (U/L) 255 (368) 5-40 
ALT (U/L) 387 (688) 5-40 
AST:ALT 0.9 (0.5)  
ALP (U/L) 329 (440) 40-120 
GGT (U/L) 455 (732) 0-35 
Albumin (g/l) 34 (8) 35-52 
Bilirubin (total) (μmol/L) 122 (147) 0-21 
Bilirubin (conjugated) (μmol/L) 85 (108) 0-6 
HbA1C (%) 9.8 (3.3) < 6% normal non-diabetic range 
Glucose - random (mmol/L) 5.8 (2.7) < 7.8 
Creatinine (μmol/L) 63 (16) Male/Female 64-104/49-90 
INR 1.2 (0.4)  
Ferritin (μg/L) 4483 (6392) Male/Female 30-400/15-150 
AFP (μg/L) 17 (22) <8 
CRP (mg/L) 15.4 (23.3) 0.0-5.0 
ESR (mm/hour) 20 (1) 0-15 
Table 1: Characteristics of patients who underwent liver biopsy.  Values reported are the 
mean, one standard deviation in brackets, and the local reported adult reference 
interval.  AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline 
phosphatise; GGT, gamma glutamyl transferase; HbA1C, glycated haemoglobin A1; INR, 
international normalised ratio; AFP, alpha fetoprotein; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate. 
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Patient  Fibrosis score SPEA (IU/l) 
1 0 582 
2 0 324 
3 1 101 
4 1 464 
5 1 201 
6 1 284 
7 1 363 
8 1 887 
9 2 206 
10 2 360 
11 2 865 
12 2 457 
13 2 498 
14 3 204 
15 3 528 
16 3 84 
17 3 554 
18 3 473 
19 3 323 
20 4 337 
Table 2:  Results of fibrosis score at biopsy and serum prolidase enzyme activity (SPEA) 
 
 SPEA  
  positive negative Total 
positive 16 2 18 
Li
v
e
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negative 16 23 39 
Total 32 25 57 
Table 3:  Results of serum prolidase enzyme activity (SPEA) discriminatory power at a 
SPEA cut-off level of 200 IU/L 
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Figures 
 
 
Figure 1:  STARD flow diagram detailing the testing process 
 
 
Eligible patients 
n = 66 
Excluded patients 
No informed 
consent: n = 8 
SPEA 
performed 
n = 58 
Abnormal result:  
n = 33 
Normal result:  
n = 25 
No biopsy: 
N = 14; 1 outlier 
Biopsy: n = 18 
Fibrosis present:  
n = 16 
Fibrosis absent: 
n = 2 
Biopsy: n = 2 
No biopsy: 
N = 23 
Fibrosis present: 
n = 2 
Fibrosis absent: 
n = 0 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 58 
Stability with freeze-thaw
0
50
100
150
200
250
300
350
400
450
0 1 2 3 4 5 6 7 8 9 10
Days
SP
EA
 
Figure 2: SPEA activity measured on one sample from a volunteer which was subjected 
to repeated freeze-thaw cycles over a number of days.  Freezing was done at -20 
o
C.     
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Figure 3: Haemolysis affects apparent SPEA levels, even at low levels of haemolysis 
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Figure 4: Bland-Altman plot comparing values on 10 samples measured using both 
Kayadibi and Myara’s method.  The solid horizontal line represents the average 
difference between the two methods. 
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Figure 5: Reference distribution of the SPEA values in the control group (n=38) after the 
square root of the SPEA values was taken
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Figure 6A:  Box and whiskers plot for serum prolidase enzyme activity (SPEA) in the 
control group versus the patients undergoing liver biopsy.  The horizontal line 
represents the median, the box 25-75
th
 centiles and the whiskers 10-90
th
 centiles. 
Figure 6B:  Box and whiskers plot for serum prolidase enzyme activity (SPEA) stratified 
on the basis of increasing degree of fibrosis.  The small box represents the median, the 
box 25-75
th
 centiles and the whiskers 10-90
th
 centiles. 
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Part C Supplemental Data 
Tables 
 
Section and Topic Item 
# 
 On page # 
TITLE/ABSTRACT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity 
and specificity'). 
46 
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or 
comparing accuracy between tests or across participant groups. 
47 
METHODS    
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where data 
were collected. 
50, 51 
 4 Participant recruitment: Was recruitment based on presenting symptoms, results from 
previous tests, or the fact that the participants had received the index tests or the 
reference standard? 
50 
 5 Participant sampling: Was the study population a consecutive series of participants defined 
by the selection criteria in item 3 and 4? If not, specify how participants were further 
selected. 
50 
 6 Data collection: Was data collection planned before the index test and reference standard 
were performed (prospective study) or after (retrospective study)? 
50, 51 
Test methods 7 The reference standard and its rationale. 50 
 8 Technical specifications of material and methods involved including how and when 
measurements were taken, and/or cite references for index tests and reference standard. 
51-54 
 9 Definition of and rationale for the units, cut-offs and/or categories of the results of the 
index tests and the reference standard. 
64,72 
 10 The number, training and expertise of the persons executing and reading the index tests 
and the reference standard. 
53,54 
 11 Whether or not the readers of the index tests and reference standard were blind (masked) 
to the results of the other test and describe any other clinical information available to the 
readers. 
53,54 
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, and the statistical 
methods used to quantify uncertainty (e.g. 95% confidence intervals). 
64 
 13 Methods for calculating test reproducibility, if done. 52 
RESULTS    
Participants 14 When study was performed, including beginning and end dates of recruitment. 50 
 15 Clinical and demographic characteristics of the study population (at least information on 
age, gender, spectrum of presenting symptoms). 
50, 63 
 16 The number of participants satisfying the criteria for inclusion who did or did not undergo 
the index tests and/or the reference standard; describe why participants failed to undergo 
either test (a flow diagram is strongly recommended). 
65 
Test results 17 Time-interval between the index tests and the reference standard, and any treatment 
administered in between. 
50 
 18 Distribution of severity of disease (define criteria) in those with the target condition; other 
diagnoses in participants without the target condition. 
50 
 19 A cross tabulation of the results of the index tests (including indeterminate and missing 
results) by the results of the reference standard; for continuous results, the distribution of 
the test results by the results of the reference standard. 
64 
 20 Any adverse events from performing the index tests or the reference standard. 55 
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Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% 
confidence intervals). 
56,57 
 22 How indeterminate results, missing data and outliers of the index tests were handled. 65 
 23 Estimates of variability of diagnostic accuracy between subgroups of participants, readers 
or centers, if done. 
 
 24 Estimates of test reproducibility, if done.      53 
DISCUSSION 25 Discuss the clinical applicability of the study findings. 57-61 
Table 1S: STARD checklist for reporting of studies of diagnostic accuracy (version Jan 
2003). www.stard-statement.org/ (accessed January 2011) 
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Figure 1S: Linearity of the prolidase assay established by measuring dilutions of a sample 
with a high SPEA level 
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Figure 2S: SPEA activity of a pooled sample aliquotted and stored at 25
o
C and assayed 
on various days 
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Figure 3S: SPEA levels in a pooled sample aliquotted and stored at -20
o
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Kayadibi vs Myara y = 0.5387x + 155.31
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Figure 4S: Linear regression plot of 10 samples analysed using Kayadibi’s method 
compared with Myara’s method 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 65 
 
 
Figure 6S:  Photomicrographs of histological examination of liver biopsies.  A: Low power 
haematoxylin and eosin (H&E) stain of a liver biopsy showing no fibrosis; B: the same 
biopsy at medium power stained with bile sirius red (BSR) which stains for fibrosis; C 
(collagen stains red): Low power H&E stain of extensive (4+) fibrosis; D: same biopsy as 
C but stained with BSR at medium power demonstrating the fibrosis. 
A B 
C D 
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Figure 6S:  Receiver operating characteristics curve analysis showing serum prolidase 
activity cut-off levels of 529, 500, 463, 450, 360, 330, 321, 280, 200 and 100 IU/L 
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Part D Appendix 
This part contains information that provides supplementary detail.  This section contains 
a copy of the University’s official guidelines which mandates the layout of this minor 
dissertation, the method used in the determination of prolidase as well as the classical 
method described by Myara et al.
29
  Further information not included in Part A - C but 
that will be of value in future research are Michaelis-Menten and Lineweaver-Burk plots, 
therefore there are included here.  In addition, the approval from the Ethics Review 
board is included, along with the informed consent form.  Finally, the “Instructions for 
Authors” downloaded from the Annals of Clinical Biochemistry are also appended.  
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Part D Appendix 
University of Cape Town’s MMED minor dissertation guidelines 
 
7. Minimum Requirements for Dissertations for MMed and MPhil for Subspecialities 
Degrees 
Following extensive discussion with Heads of Divisions , Dr S Ka lula and Prof S Kidson recommend the 
fo llowing minimum criteria for dissertations for MMed and MPhil (subspeciality) degrees: 
UNIVERSITY OF CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
MMedfMPhil Part III (minor dissertation ) 
Guidelines for candidates, supervisors and examiners 
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Michaelis-Menten analysis 
Michaelis-Menten analysis was undertaken using a pooled serum sample and a wide 
range of glycyl-proline substrate concentrations (10 – 1 000 mmol/l).  SPEA activity was 
determined and plotted against substrate concentration as shown.  A double reciprocal 
(Lineweaver-Burk) plot was also done to ascertain a Km value of 24.8 mmol/l and a 
Vmax of 1 668 IU/l. 
SPEA 
Gly-Pro conc. 
(mM) 
482 10 
835 50 
1914 500 
1766 1000 
Table 1: SPEA values obtained at various glycyl-proline concentrations.  SPEA: serum 
prolidae enzyme activity; gly-pro: glycyl-proline. 
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Figure 1: Michaelis-Menten plot of reaction rate versus substrate concentration using 
the data presented in Table 1 
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Lineweaver-Burk plot 
1/v 1/s 
0.002 0.1 
0.001 0.02 
0.001 0.002 
0.001 0.001 
0 -0.04027 
Table 2:  The reciprocals of the values presented in Table 1 
 
Lineweaver-Burk plot
y = 0.0151x + 0.0006
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Figure 2: The reciprocals shown in Table 2 were plotted in a Lineweaver-Burk (double 
reciprocal) plot. 
 
Thus from the Lineweaver-Burke plot 
Km  24.83 mmol/L 
V max 1666.67 IU/L 
Table 3:  The y-intercept of Figure 2 yielded a value for 1/Vmax; likewise, the x-intercept 
yielded –Km.  Therefore, Vmax and Km can be determined. 
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Serum prolidase assay standard operating procedure (SOP)                                             
 
Reagents: 
Serum diluent:  40mM Tris HCl pH 8.0 containing 2.5mM MnCl2  
Substrate:  100mM gly-pro  (17.2mg/ml)- dissolve 86mg in 5ml water, (stored frozen in 
1ml aliquots) 
Buffer:  Tris HCl 100mM pH 8.0; dissolve 0.24g Tris (free base) in ±15ml water, pH to 8.0 
then make up to 20ml. Store at 4
o
C.  
Stopping reagent:  20% TCA (w/v)  
Proline stock standard:  10mM proline in 6.7% TCA. Dissolve 5.8mg in 5ml 6.7% TCA  
Proline standard diluent:  6.7% TCA 
Chinard’s reagent: Mix 23.7ml water, 60ml glacial acetic acid and 16.3ml 85% H3PO4 
(d=1.7). Add 2.5g ninhydrin and heat at 70
o
C to dissolve. 
 
 
Method: 
Prepare 2 microfuge tubes for each serum to be assayed thus (volumes in µl) 
blank    test 
serum      5   5 
serum diluent    15   15 
 
                                                       Incubate 2h at 37
o
C 
 
20% TCA     100   - 
#gly-pro 100mM    60   60 
#Tris 100mM pH 8.0   80   80 
#water     40   40 
# [Note: these last 3 reagents can be pre-mixed as a ‘cocktail’ immediately before use in 
a ratio of gly-pro:Tris:water of 3:4:2, and add 180µl per tube]   
 
                                             Mix well and incubate at 37
o
C for 30min 
 
20% TCA     -   100  
 
Mix and spin down protein pellet. Assay supernatant fluid (snf) proline content alongside 
proline standards by pipetting into fresh microfuges as follows (volumes in µl): 
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Standard Curve 
Proline standards (mM)   0  0.5  1 
6.7% TCA    200  190           180   
10mM Proline in 6.7% TCA    0   10           20          
 
Blank and tests 
Assay snf’s (blanks and tests)          -  -  -  200 
Glacial acetic acid    400  400  400  400 
Chinard’s reagent    400  400  400      400 
Heat 10min at 90
o
C transfer to disposable plastic 1ml cuvettes and read absorbance at 
515nm against the zero proline standard. 
 
Calculation 
Determine proline concentration in the sample tests and blanks in mmol/l off the 
standard curve. 
Subtract blanks from test (T-B). 
Serum prolidase activity  
= (T-B) x 200/5 x 1/30 x 1000 = (T-B) x 1333 μmol/min/litre  
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SOP for Myara’s modification prolidase assay29 
 
MW 
• Glycyl-L-proline = 410.28  
• Glacial acetic acid [CH3COOH] = 60 
• Orthophosphoric acid [H3PO4] = 98 
• Ninhydrin = 178.14 requires no special care or attention and absorbs maximally 
@ 440nm. 
• TCA = 163.38 
• Tris HCl [C4H11NO3ClH] Tris= 121, Tris HCl = 158 
• MnCl2  = 126 
• Proline = 115 
 
Reagents 
Chinard’s reagent:  
Mix: 
• 600 mL of glacial acetic acid 
• 400 mL of 6 mol/L orthophosphoric acid (407 mL of orthophosphoric acid 85%, d 
= 1.7, and 593 mL of water) 
• Dissolve 25g of Ninhydrin in this mixture at 70
o
 C. 
 
Standard proline solution:  
This is a 650 μmol/L solution in 0.45 mol/L trichloroacetic acid.   
Mix: 
• proline 74.75 mg  
• TCA 73.35g  
• 1 L water 
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Buffer Mixture 
0.05 mol/L Tris HCl buffer, pH 7.8, containing 1 mmol of MnCl2 per litre. 
• Tris 5.93 g 
• Tris HCl 0.078 g 
• MnCl2 126 mg 
• 1 litre water 
 
Glycyl-L-proline:  
94 mmol/L glycyl-proline in 0.05 mol/L Tris HCl buffer, pH 7.8, containing 1 mmol of 
MnCl2 per litre. 
Mix: 
• glycyl-proline 38.54g  
• 1 Litre buffer mixture 
 
 
Sample preparation 
Collect venous blood into heparinized tubes (EDTA, fluoride, and sodium citrate are all 
inhibitors) and separate the plasma by centrifugation at 2300 x g for 15 mm. Discard 
haemolysed samples because erythrocyte prolidase activity is relatively high.  
Store plasma samples at -20
o 
C until assay. 
 
Method 
 Blank Control Standard Sample 
Plasma    100 
Buffer mixture    500 
Incubate x 24 hours @ 37 degrees C 
SNF  -  100 
Glycyl-proline solution  100  100 
0.45 mmol TCA  1 000  - 
Incubate x 30 minutes at 37 degrees C 
0.45 mmol TCA  -  1 000 
SNF  100   
centrifuge at 10,000g at 4 °C for 10 min.  Then in lockable eppendorf tubes 
SNF 250 μl of 0.45 
mmol TCA 
250 SNF  250 proline 
standard 
250 
Glacial acetic acid 500 500 500 500 
Chinard’s reagent 500 500 500 500 
Heating block x 10 minutes at 90 degrees C 
Read the absorbance at 515 nm against the blank. 
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Calculate the enzyme activities as follows: 
For proline determination, we took 0.5 mL from a total 
volume of 1.2 ml 
 
   = millimoles of proline formed per 0.1 mL of plasma, during 30 
min where  
E is the experimental tube absorbance 
C is the control absorbance 
S is the absorbance of the standard 
[SI is the concentration of the substrate in mmol/L. 
If we express the result per litre of sixfold diluted plasma, 
during one minute, we obtain: 
 
Millimoles of proline formed per litre of plasma per minute at 37 
o
 C at pH 7.8. 
Simplifying the equation: 
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Fibroblast culture SOP 
Objective  
Fibroblasts are grown from skin biopsies for diagnostic purposes. They provide a source 
of enzymes to diagnose diverse inherited metabolic diseases. 
 
Materials and Reagents 
All reagents are stored in the tissue culture fridge/freezer 
• Gibco Dulbecco’s modified eagle’s medium (DMEM), stored at 4
o
C  
• lonza DMEM, stored at 4
o
C  
• Sigma Foetal calf serum, stored at -20
o
C  
• Gibco foetal calf serum, stored at -20
o
C  
• Gibco 200mM Glutamine, stored at -20
o
C  
• Antibiotics - Add streptomycin 2 g, penicillin 2 g and neomycin 2 g to 100 ml 
sterile normal saline (0.9%).  Filter sterilize and aliquot 2.5ml into 5ml sterilin 
containers, store at -20
o
C 
• Trypsin - Add EDTA 0.4 g, NaCl 16.0 g, KCl 0.4 g, Na2 HPO4  2.3 g, KH2PO4 0.4 g, 
glucose 0.4 g and trypsin 2.5 g to 200 ml sterile water.  Check and adjust pH 7.2 - 
7.4.  Filter sterilize and store at -20
o
Cin 10ml aliquots.  Working solution - add 
10ml of stock trypsin to 90ml distilled sterile H2O; final concentration: trypsin 
0.125 % in 0.5 mmol/l EDTA, Phosphate 10mM  
 
Complete tissue culture medium 
Add 50ml 10% Sigma or Gibco Foetal calf serum (FCS), and 5 ml 200 mM glutamine to 
500ml Gibco or Lonza Dulbecco’s modified eagle’s medium +; bottles are labelled A or B.  
Add 2.5ml of the combined antibiotics to 500ml of culture medium to obtain a final 
concentration of 100 units/ml.  If glutamine or antibiotics are added this must be noted 
on the bottle as well as the date the medium was made up. Cell lines are cultured in 
duplicate using two different manufacturers, the medium must only be used by one 
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person, no sharing of medium should be allowed. Before using the culture medium, 
transfer 5ml into a 25cm
2 
sterile flask and incubate for 3 days to check for 
contamination in the medium. 
 
Disposables 
• 5ml sterilin containers 
• Scalpel Blades No. 23 
• 22cm x 22cm glass cover slips dipped in 70% alcohol and flamed. 
• Forceps 
• 35mm Petri dishes 
• 25cm
2 
flasks 
• 75cm
2
 flasks 
• 2ml cryotubes 
• 15ml conical centrifuge tubes 
• Individually wrapped sterile pipettes 
o 5ml pipettes 
o 10ml pipettes 
o 25ml pipettes 
• 0.22μm sterile filters 
 
Specimens 
Skin biopsy is taken sterilely and placed in 2.5ml culture medium containing antibiotics. 
The specimen should ideally be processed on the same day as taken. It is nevertheless 
possible to get cell growth after 3-4 days later provided the specimen is placed in cell 
culture medium and kept at 4
o 
C. If culture medium is not available the biopsy can be 
put in sterile saline, but then it must be processed within 24hrs.   
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Preparation 
• Using two scalpel blades finely slice the tissue into little pieces in a 35mm Petri 
dish and cover with a drop of culture medium containing antibiotics.   
• Dispense the tissue fragments into several 35mm Petri dishes, cover with a 
flamed cover slip and add 2.5 ml culture medium containing antibiotics. Incubate 
at 37
0
C in a 10% CO2 incubator. 
• When there is a fairly confluent growth of fibroblasts (not epithelial cells), invert 
the coverslip, cell side up, into a clean 35mm Petri dish. Add 2.5ml culture 
medium. Once the fibroblasts are reasonably confluent, they can be trypsinised 
and seeded into 25cm
2
 flasks (one 35mm Petri dish per one 25cm
2
 flask).  
• This is the 1st passage. 
• When the 25cm
2
 flask is confluent, it is trypsinised and seeded into a 75cm
2
 
flask, this is the 2
nd
 passage. Two confluent 75cm
2
 flasks are harvested and 
frozen in liquid Nitrogen for further studies. 
 
Maintenance 
• 35mm Petri dishes: 2.5ml culture medium containing antibiotics removed and 
replaced twice a week until cells are confluent. 
• 25cm
2
 and 75cm
2
 flasks: culture medium without antibiotics is removed and 
replaced twice a week (5ml and 12ml respectively) until cells are confluent. Once 
fibroblasts are confluent, they must be trypsinised and seeded into fresh flasks. 
If left for too long the fibroblasts will lift off the bottom of the flask and die. 
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Trypsinization 
Petri dish 
Remove medium and wash twice with 1ml trypsin working solution. After the 2nd wash, 
add 0.5 ml trypsin solution and put in incubator until cells detach (generally 2-3min), but 
NOT longer then 15mins, as prolonged exposure to trypsin can damage the cell 
membrane. Transfer the trypsin and fibroblasts into a 25cm
2
 flask and add 5ml culture 
medium immediately to neutralize trypsin. The FCS in the tissue culture medium stops 
the action of trypsin.  
25cm
2
 Flask  
Pour off medium and wash twice with 2ml trypsin.   Add 1ml typsin and put in incubator 
until cells are off the surface. Tap side of flask to dislodge cells and transfer cells as 
follows: 
1 x 25cm
2
 flask into 3 x 25cm
2
 flasks add 5ml culture medium into each flask 
1 x 25cm
2
 flask into 75cm
2
 flask add 12ml culture medium to flask. 
75cm
2
 Flask  
Pour off medium and wash twice with 4ml trypsin.  Add 2ml trypsin to dislodge cells, 
transfer the cells into 3 x 75cm
2
Flasks and add 12ml of culture medium to each flask. 
 
Freezing procedure 
• Freezing Medium: DMEM with 20% FCS and 10% glycerol 
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• Two 75cm
2
 confluent flasks are trypsinized, the cells pooled and transferred into 
a 15ml sterile conical tube and topped up with culture medium. Centrifuge for 
10min at 1000rpm. Medium is discarded, 5ml culture medium added and 
centrifuged as above. The medium is discarded and cell pellet resuspended in 
7ml of freezing medium. 
• Aliquot 1 ml of cell suspension into 7 x 2ml sterile cryotubes.  
• Place a drop of the cell suspension into two 35mm Petri dishes containing a 
sterile cover slip, add 2.5ml of culture medium without antibiotics and incubate 
for two to three days for mycoplasma testing.  
• The 2ml cryotubes are placed in the nalgene freezing container, containing 
250ml Propyl alcohol and placed in the -80
o
C freezer for a minimum of 4h. The 
tubes are then carried in liquid nitrogen to the liquid nitrogen storage containers 
and placed in the boxes. One vial is thawed, put into a 25cm
2
 flask containing 
5ml culture medium and incubated for three days as a control to check for 
viability and exclude contamination. 
 
Quality Control 
Culture each cell line in duplicate using two different manufacturers of DMEM and 
Foetal Calf serum. At the time of freezing the cells are plated for mycoplasma testing 
and tested immediately. Cells are grown in antibiotic-free medium as the presence of 
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antibiotics can mask contamination with mycoplasma. If bacterial contamination is 
noted, cells are immediately discarded.  
 
Reference: 
R. Ian Freshney: Culture of animal cells. A manual of Basic techniques.  Wiley 2005 
(ISBN: 0471453293) 
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Ethics Approval 
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" 
09 October 2009 
REC REF; 435/ 2009 
Dr JC StanRie t 
el7 
NGSII 
Dear Dr Stanflic i 
H ealth Sciences Faculty 
Research Ethics Commince 
Room £52-24 Groote Schuur H ospital Old l\lain Building 
O bsc£vatO£Y 7925 
Telepbone [021 ]406 6338 • Facsimile [021J -W6 6411 
c·m ail; nosi.ryw~bi@uct.ac.7:I 
PROTOCO L TITLE; EVALUATION OF SE RUM PRO UDASE ACTIVITY AS A MARKER F O R 
LIVER FIB ROSIS IN SUSPECTED LIVE R DISEASE 
l nank you for submitnng your srudy [0 rhe Research Ethics Conunincc for rc,;ew. 
It is a pleasure to infonn rou that the Ethics Committee has fonn aLly approved me abo'·e mentioned study. 
Approval is granted for one year unt il 16 October 2010. 
Please submil an anmL11 progress report if the ~rudy extends beyond the appro"al period. Altcmativcly, please 
submit a brief summary of your findings so that we can close our records. 
Please note that the ongoing ethical conduct of the srudy remains the responsibility of the principal 
in'·esnga[Or. 
Yours sincerely 
;") PROFE SSOR M I}LOCKMAN P( CHAIRPE RSON H SF H lIMAN ETHI CS 
This serves [0 confirm that the University of Cape Town Research Ethic~ Committee complies to the Erhics 
Standards for Clinical Research with a new drug in patients, based on the t.ledical Research Council (MRC· 
SA), Food and Drug Administration (FDA-USA), International Con\'cntion on Hannonisation Good Clinical 
Practice (lCH Gel') and Dcclaration of Iidsinki guidelines. 
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3. Protocol summary 
Total number of records or specimens collected, reviewed or stored since the original 68 
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Consent Form 
 
DEPARTMENT OF CHEMICAL PATHOLOGY 
UNIVERSITY OF CAPE TOWN 
 
CONSENT FORM 
 
Investigators: Prof Tahir Pillay, Dr John Stanfliet 
 
EVALUATION OF SERUM PROLIDASE ACTIVITY AS A MARKER FOR LIVER FIBROSIS IN 
SUSPECTED LIVER DISEASE 
 
Currently, when someone is thought to have scarring of the liver, the only way to tell 
for sure is to do a biopsy; that is, to insert a needle into the liver, and look at the cells 
under a microscope.  However, this can be a problem because of pain, fear and the 
need for specialist pathologists to examine the cells.  We are looking for an enzyme in 
the blood that may indicate that there is scarring of the liver, and also indicate the 
degree of scarring.   
 
The blood that is being taken from you will be tested for the activity of this enzyme 
called prolidase and then analyzed for different protein and enzyme concentrations.  
 
I, ………………………………………………………, agree to participate in the above study 
and hereby give permission that blood may be taken and serum analysed and/or 
stored.  
 
I understand that I will undergo the following investigations: 
 
i. Venous blood will be taken for a serum prolidase activity test and the 
measurement of serum proteins and enzyme concentrations. 
ii. I further understand that a portion of these blood samples will be 
stored for: 
a) possible reanalysis 
b) analysis when the study is completed, if additional information 
has become available 
c) further research purposes, subject to the approval of the 
University of Cape Town Research Ethics Committee and that 
any information from such research will remain confidential 
d) I understand the results of these tests will not become available 
to me 
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I have been informed that:   
a) the investigators are under the obligation to respect medical 
confidentiality  
b) No DNA will be stored and no genetic/DNA tests will be done on 
these samples 
c) All samples will be anonymised prior to being sent to the 
laboratories.   
 
I UNDERSTAND THAT THIS STUDY WILL BE OF NO BENEFIT TO ME AND ONCE MY BLOOD 
HAS BEEN TAKEN, THERE WILL BE NO WAY TO TRACE IT BACK TO ME. 
 
 
 
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS HAVE BEEN ADEQUATELY ANSWERED 
 
 
 
Participant: Name  …..………………………… Date: ……………….. 
 
 
 
Participant: Sign …….....……………………. Date: ……………….. 
 
 
 
Informed consent obtained by: Name ………………………….    
    Sign  …………………………. 
 
 
 
Witness: …………………………………… Sign: ….…..………. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 95 
Annals of Clinical Biochemistry - Instructions to authors  
 
Annals of Clinical 
Biochem istry 
S~arch this journa l 
L ~~ 
Advanced sea rch 
Home Current issue Browse archive Alerts About the journal Feedback 
Annals of Clinical Biochemistry Guidelines for Authors 
SUBMIT YO UR ARTI CLE O NLINE 
For detai ls of benefits offered to RSM Press authors, pleaS{: v isit Ollr benefits pagt . 
For details of our policy on depositing articles in institutiooal or cent ral repoSitories, pleilse visit our archiVing 
-. 
For detai ls of our policy on opt:n access articles, please visit Ollr R5M OQf:O (}flge. 
For referee guidelines, pleaS{: visit our rderee page. 
These instructions comply with the Uniform Requirements for M,lnuscripts Submit ted to Biomedica l .loum als 
formutd ted by the Intemational Committee of Medical Joumal Editors (for further tkta ils, Sf:{: the ICMJE sil t ) 
All articles subm itted to the Anna ls of Ciinic ill Bioche mistry must comply w ith the instmct ions 
below. Fililure to do so w i ll r esu lt in return of the millll iscri pt ilnd pos!>ible delay in publica tion, 
1, A ims ilnd scope 
The Annals of Clinical Biochemistry accepts papers tha t con tribute to knowledge in all fields of clinical 
biochemistry, espec la lly t hose appertain ing to the understilnding, diagnosis and t reatment of disease in 
hUmilns. It publ ishes papers on cl in ica l audit , metabolic mediane, immunology, genetiCS, biotechnology, 
haemat ology, computing and managelTX:nt where they have both biochemical and clinical relevance. Papers 
describing evaluation or implementation of commerclal reagent k its or the perfOf'mance of new analysers 
require !>ubstantial original infOf'mation. 
Research undertaken in non-human animals wi ll not be considered for publ ication in t he Anna ls. 
2. Editoria l po licy 
Covenng letter 
The covering letter is important. To help the EditOf' in his prel im inary evaluation, please indicate why you th in 
the paper suitable for publ ication. If your paper should be considered for fast -track publication, please explain 
why. 
Peer review 
All papers submitted for publ icatioo undergo peer review. 
Ethical appmval 
All research submitted for publication must be appmved by an eth ics committee and the eth ical approval 
nurnbt:r included in the declarations (see below). 
Patient consent 
Any article conta ining identiflable patient information must be accompanied by a let ter from the authors 
confirming that the pat ient has given written infOflT'l{od consen t to publica t ion. Pa t ient 's nalTX:s, init ials or 
hospita l numbers should never be published in written descriptioos. other information (age, gender, race, etc 
should only be included where it is essentlal fo r scientific purposes and the patien t (or parent or guardian) ha~ 
given written informed consent. The Editors may also ask authors to remove personal informat ion t hat , whilst 
interesting and colourfu l, does not add to the substance of an arti cle, but does increase the likelihood of 
parties being identified. If there is any doubt abou t whether or not in formation is identifiable, the Editors are 
happy t o discuss this before an article is submitted. Reviewers wi ll also be asked to take careful account of 
issues reta t ing to patient confidentiality when reviewing articles. 
Gase studies are not the only kinds of article to wh ich this rule will be appl ied, but they wi ll be subject to 
additional scrut iny . Not on ly should submissions be accompanied by the letter confirm ing written informed 
consen t , but the Editors also expect to be informed about the measures that have been taken to anonymise 
the deta ils tha t could have led to parties being identified. They also reserve the right to WOf'k with the author~ 
to mah: additional anonymising changes as they or the rev iewers see fit. 
I n order to ensure that va luable and novel issues are aired, t he Editors will sometimes conSider publishing 
cases studies that conta in potentially identifiable informat ion where it has been impossible or clearly 
undf:sirable t o seek consent from relevant parties. However, given the st rong preference for consent having 
been sought and obtilined the reasons fOf' not seeking consent must be compelling, and the public interest 
arguments for publishing the case must be powerful. I n cases where consen t has not been obta ined, the 
authors must provide a statement from a Medica l Director or equiva lent that the hospitil l or medical centre is 
happy f or the case t o be published. 
Please d o not submit the patient's actual written informed consent with your article, as this in itse lf breaches 
the pa t ient 's confidf:ntiality. The Journal requests tha t you confirm to us, in writing, t hat you have obtained 
written informed consent but the written consent itsert should be held by the authors/ investigators 
themselves, for example in a patients hospjtal record. The confirma tory letter may be uploaded with your 
submission as a supplementary f ile . 
Should vou require a template form for obta ininq written informed consent, th is can be sUDOlied bv e-mailinq 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 96 
 
provides consultative advice to lab Tests ltd. 
Funding: This research was funded by the University of York 
Ethica l appmval: The eth ics committee of Northern Yorksh ire approved this study (REC numtit:r: GH2333 5H) 
Guarantor: EF 
Cont ributorship : lM and HG researched literature and conceived the study. EF was involved in protocol 
development, gaining ethical approval, patient recruitment and data analysis. AB wrote the first draft of the 
manuscript. All authors reviewed and edited the manuscript and approved the fina l version of the manuscript 
Acknowledgements: We would like to thank Sarah Powells for her assistance and guidance in this research . 
We wou ld also like to thank GIobt:scape pic for providing reagents at a reduced cost. 
Permissions 
All previously published material must tit: accompanied by the written con sent to reproduction of the copyright 
holder. An acknowledgement of permission should be included at the re levant point in the paper, and a full 
reference to the OI"iginal ptace of publication should be included in the reference list . 
Copynght 
Authors of accepted manuscripts will be required to allocate copyright t o the Associat ion for Clin ical 
Biochemistry prior to publication. 
3. Types of articles 
Editonals 
Articles referring to research published elsewhere in that issue of the jou rnal, or to important events in clinical 
biochemistry. EditOl"ials are generally invited. 
Personal Views 
Articles pertinent t o cl inical and scient ific developments or to the pract ice of clin ica l biochemistry. Personal 
Views are generally invited. 
Review Ntides 
Articles of a substantial and topical nature. Review Articles are generally invited. 
Or"iginal Articles 
Articles describing substant ial original research that fa lls with in the scope of the journal. hese should be up 
to 5000 words, including an Abst ract, and have no more than six figures and tables. Structured headings are 
required. 
Short Reports 
Brief technica l notes and pre liminary communicat ions. These should be less than 1000 words, including an 
Abstract, and have only one small figure or table and no more than six references. Structured headings, 
including a conclusion, are desirable. 
Case Reports 
Articles describing clinical cases tha t have significant original observations, are instructive, include adequate 
methodological details and provide conclusions. These should tit: up to 2000 words, including an Abstract, and 
have no more than two figures and tables. Structured headings are desirable. Please note the above 
comments regarding obta ining written info fITt{od consen t . 
Letters to the Editor 
letters arise n01TThl11y but not exclusive ly from papers published in this and other scient ific journals. These are 
usually less than 500 words. 
Book Reviews 
Commissioned by the Book Review Editor, Dr Andrew Day, c/o ACB Office , 130- 132 Tooley Street, london 
SEt 2TU, UK 
Journal Watch 
Short rev iews of recently published articles of interest to clin ica l biochemists. These are usually less than 500 
words. 
","seator 
An entelt aining end piece to the journal, written by the Piscatrix . 
4 . Ho w to submit a manuscript 
Only manuscripts submitted via the onl ine manuscript submission and peer review site, which can tit: found at 
http://mc.manuscriotcent ra l,com/acb will beconsideredforpublication . 
All submissions must tit: in English. 
Tables and figures may be submitted as separate files, in which case the files should be uploaded in the 
following order : ( 1) main text, including t itle page, abstract and references; (2) t ables; (3) figures; (4) 
supplementary files; and ( 5) author proforma . 
File fomlilfS 
Text files must tit: saved in .doc or .rtf format. Other sUitable forma ts inc lude .tif for photographic images, .xls 
for graphs produced in Excel, and .eps for other line drawings. 
5. Ho w to prep<lre a manuscript 
Formarting 
Manuscripts must be submitted using double line-spaced, unjustified text throughout, with headings and 
subheadings in bold case . Press 'Enter only at the end of a paragraph, list en t ry or heading. 
TItle page 
The first page should contain the full t it le of the manuscript , a short t it le, the author(s) name(s) and 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 97 
 
www.acb.rsmjournals.com/misc/authors (accessed 10/01/2011) 
 
 
affiHat ion(s), and the name, postal and email addresses of the author f or correspondence, as we ll as a full list ' 
of df:d arat ions. 
The t it le should be concise and informative, accurately indicat ing the content of the artide. The short title 
should be no more than six words long. 
The correct ordf:r for dedarat ions is : competing interests, funding, ethical approval (including reference 
nurTlbtor), guarantor, contributorship, acknowledgements. 
Abstract 
A structured abstract of no more than 2 50 words must accompany all Review Articles, Original Articles and 
Short Reports. The abstract should normally use four headings: Background (context and rat ionale); Methods 
(type of study, patients, materials, techniques); Resuits (main numerical data and statistical information); and 
Conclusions (main objective and verifiable conclusions). Personal Views and Gase Reports should be 
accompanied by an unst ructured abstract of up to 250 words. letters t o the Editor do not require an abstract. 
Tables 
Tables must be prf1Xlred using the Table fea ture of the word pmcessor. Tables should not duplicate 
infolTThl t ion given in the text , should be numberf:d in the ordf:r in which they are ment ioned in the text, and 
should be given a bl"ief t it le. 
Figures 
All f igures should be numbered in the order in which they are mentioned in the text. All figures must be 
accompanied by a figure legend. If figures are suppl ied in separate fi les, the figure legends must all be listed 
at the end of the main text file. 
Une drawings should be produced electron ica lly and dearly labelled using a sans serif font such as Arial. 
Graphs may be supplied as Excel spreadsheets (one per sheet). other line drawings should be supplied in a 
sU itable vector graphic file forma t (e.g .. eps) 
All photographic images should be submitted in camera-ready form (i.e. with all extraneous areas removed), 
and where necessary, magnificat ion should be shown using a scale marker. Photographic images must be 
supplied at high reso lut ion, preferably 600 dpi. Images supplied at less than 300 dpi are unsuit able for print 
and will delay publicat ion. The preferred fi le forma t is .t if . 
References 
Only essenUal references should be includf:d. Authors are responsible f or verify ing them against the original 
source materia l. RSM Press uses the Vancouver referenc ing system: references should be ident ified in the 
text by superscript Arabic numerals after any punctua t ion, and numbered and listed at the end of the paper in 
the order in which they ilre first cited in the text . Automat ic numbering should be avoided. References should 
include the nilmes and initials of up to six authors. If there are more than six authors, on ly the first three 
should be named, fo llowed by et al. Publications for which no au thor is apparent may be attributed to the 
organization from which they originate. Simply omit the name of the author for anonymous Joumill alt icles -
avoid using 'Anonymous'. Punctuat ion in references should be kept to il minimum, as shown in the following 
examples: 
1. Baynes 1, Oominiczak M. Medical Biochemistry. Philadelphia : Mosby, 1999 
2. Aoozguia K, Phan TT, Shivu GN, et al. I nsights into how to conduct a d inica l tria l in the UK. J R Soc Med 
2007; 1 00:469- 72 
Ablxeviations 
Symbols and abbreviat ions should be those cUlTently in use. Authors should not crea te new abbreviations and 
acronyms. The RSM's book Units, Symbols and Abbreviations provides lists of approved abbf"eviations. 
Units 
All measurements should be expressed in SI units. 
Statistics 
If preparing statistica l data for publication, pleilse read the sta t ist ical Quidel ines. 
6. Proo fs and eprints 
Proofs wi ll be sent by email to the designated colTesponding author as a PDf file attachment and should be 
correctf:d and retumed prompt ly ; cOlTections should be kept to a minimum. 
A PDf eprint of each published article wi ll be supplied free of charge to the author for cOlTespondf:n c:e ; 
hardcopy offprints may be ()f"dered from the publ isher when the proofs are retumed. 
